About: A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals
Creator	Yuen, Kwok-Yung Miorin, Lisa Yin, Xin Sun, Ren Martinez-Sobrido, Luis »more»
source	BioRxiv; Medline
abstract	The emergence of novel SARS coronavirus 2 (SARS-CoV-2) in 2019 has triggered an ongoing global pandemic of severe pneumonia-like disease designated as coronavirus disease 2019 (COVID-19). To date, more than 2.1 million confirmed cases and 139,500 deaths have been reported worldwide, and there are currently no medical countermeasures available to prevent or treat the disease. As the development of a vaccine could require at least 12-18 months, and the typical timeline from hit finding to drug registration of an antiviral is >10 years, repositioning of known drugs can significantly accelerate the development and deployment of therapies for COVID-19. To identify therapeutics that can be repurposed as SARS-CoV-2 antivirals, we profiled a library of known drugs encompassing approximately 12,000 clinical-stage or FDA-approved small molecules. Here, we report the identification of 30 known drugs that inhibit viral replication. Of these, six were characterized for cellular dose-activity relationships, and showed effective concentrations likely to be commensurate with therapeutic doses in patients. These include the PIKfyve kinase inhibitor Apilimod, cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825, and ONO 5334, and the CCR1 antagonist MLN-3897. Since many of these molecules have advanced into the clinic, the known pharmacological and human safety profiles of these compounds will accelerate their preclinical and clinical evaluation for COVID-19 treatment.
has issue date	2020-04-17(xsd:dateTime)
bibo:doi	10.1101/2020.04.16.044016
bibo:pmid	32511357
has license	biorxiv
sha1sum (hex)	b5c8a5acd44e5c0950e3771e6567c0321fe9c715
schema:url	https://doi.org/10.1101/2020.04.16.044016
resource representing a document's title	A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals
has PubMed identifier	32511357
schema:publication	bioRxiv
resource representing a document's body	covid:b5c8a5acd44e5c0950e3771e6567c0321fe9c715#body_text
is schema:about of	named entity 'The' named entity 'typical' named entity 'drugs' named entity 'emergence' named entity 'CCR1' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software